Movement Alert｜Gilead Sciences Rises 3.15% in Regular Trading, $7.8 Billion Arcellx Acquisition Continues to Lift Sentiment

Market Focus08-19 21:51

On August 19, Gilead Sciences rose 3.15% in regular trading, trading at $147.9/share, with turnover of $103 million. The rally marks a second consecutive session of gains following the company's announcement of a major oncology-focused acquisition.

On August 18, Gilead Sciences announced it would acquire cancer therapy developer Arcellx at an equity value of $7.8 billion, paying $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium over Arcellx's prior closing price. The deal is widely viewed as a strategic move to significantly strengthen Gilead's oncology pipeline. Continued positive sentiment from the acquisition, combined with solid Q2 fundamentals — revenue of $7.8 billion beating estimates and full-year adjusted loss guidance narrowed to $0.30-$0.65 per share versus the analyst consensus of $0.75 loss — has sustained upward momentum in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131060240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131060240","market":"us","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Rises 3.15% in Regular Trading, $7.8 Billion Arcellx Acquisition Continues to Lift Sentiment","media":"Market Focus","content":"<p><p>On August 19, Gilead Sciences rose 3.15% in regular trading, trading at $147.9/share, with turnover of $103 million. The rally marks a second consecutive session of gains following the company's announcement of a major oncology-focused acquisition.</p><p>On August 18, Gilead Sciences announced it would acquire cancer therapy developer Arcellx at an equity value of $7.8 billion, paying $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium over Arcellx's prior closing price. The deal is widely viewed as a strategic move to significantly strengthen Gilead's oncology pipeline. Continued positive sentiment from the acquisition, combined with solid Q2 fundamentals — revenue of $7.8 billion beating estimates and full-year adjusted loss guidance narrowed to $0.30-$0.65 per share versus the analyst consensus of $0.75 loss — has sustained upward momentum in the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Rises 3.15% in Regular Trading, $7.8 Billion Arcellx Acquisition Continues to Lift Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Rises 3.15% in Regular Trading, $7.8 Billion Arcellx Acquisition Continues to Lift Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, Gilead Sciences rose 3.15% in regular trading, trading at $147.9/share, with turnover of $103 million. The rally marks a second consecutive session of gains following the company's announcement of a major oncology-focused acquisition.</p><p>On August 18, Gilead Sciences announced it would acquire cancer therapy developer Arcellx at an equity value of $7.8 billion, paying $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium over Arcellx's prior closing price. The deal is widely viewed as a strategic move to significantly strengthen Gilead's oncology pipeline. Continued positive sentiment from the acquisition, combined with solid Q2 fundamentals — revenue of $7.8 billion beating estimates and full-year adjusted loss guidance narrowed to $0.30-$0.65 per share versus the analyst consensus of $0.75 loss — has sustained upward momentum in the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1131060240","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131060240","pubTimestamp":1787147503,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, Gilead Sciences rose 3.15% in regular trading, trading at $147.9/share, with turnover of $103 million. The rally marks a second consecutive session of gains following the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势警报|吉利德科学常规交易上涨3.15%，78亿美元收购Arcellx继续提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On August 19, Gilead Sciences rose 3.15% in regular trading, trading at $147.9/share, with turnover of $103 million. The rally marks a second consecutive session of gains following the company's announcement of a major oncology-focused acquisition.On August 18, Gilead Sciences announced it would acquire cancer therapy developer Arcellx at an equity value of $7.8 billion, paying $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium over Arcellx's prior closing price. The deal is widely viewed as a strategic move to significantly strengthen Gilead's oncology pipeline. Continued positive sentiment from the acquisition, combined with solid Q2 fundamentals — revenue of $7.8 billion beating estimates and full-year adjusted loss guidance narrowed to $0.30-$0.65 per share versus the analyst consensus of $0.75 loss — has sustained upward momentum in the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131060240","isCrawlerRequest":true}